Genomic Health, Inc. (GHDX) a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer scored a base breakout and a new FusionIQ Short Squeeze. With a whopping 40.00 + % of its float short and a point and figure target of $ 32.50 GHDX shares offer investors solid upside potential over the int. term.
Did you also know that Fusion offers money management services? Take our complimentary risk profile at www.fusioninvest.com/riskprofiler or call us toll free at 1-888-661-2022 to set up a call with an advisor.